Drug intelligence / Profile preview

Picozyme Q

Development stage: Unknown
Lead developer: PICO Entech
Modality: Small Molecules
Administration: Oral

Overview

Picozyme Q is a health supplement developed by PICO Entech that combines aldehyde dehydrogenase (ALDH) derived from dried yeast with Coenzyme Q10 (CoQ10). It is primarily indicated for the management of cancer-related fatigue, particularly in patients undergoing chemotherapy, by supporting the metabolism of toxic aldehydes and providing antioxidant activity. Additionally, it is promoted for its potential to reduce blood pressure and provide general antioxidant support. The product is currently undergoing researcher-initiated clinical trials at Korea University Anam Hospital to evaluate its efficacy in mitigating fatigue in cancer patients.

Brand names: Picozyme Q
Other names: 피코자임 큐

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on Picozyme Q.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picozyme Q.

Explore the full profile